Invesco India Pharma and Healthcare Fund

The fund's XIRR and rolling return data are not available, so a direct like-for-like comparison against category SIP XIRR averages (ranging from 12.08% for 1Y to 19.6% for 5Y) cannot be made. The only visible return data point is a calendar year 2026 return of -3.59%, indicating recent underperformance in absolute terms. Investors should request return history before evaluating this fund against sectoral peers.

Risk metrics appear unusually benign, with a maximum drawdown of just -0.11% lasting 30 days and an average drawdown of -0.05%, which is atypical for a sectoral equity fund and may reflect a short or favorable measurement window. One drawdown event exceeding 10% is recorded, though the recovery duration is listed as unavailable. Given the absence of XIRR and volatility data, risk-adjusted return assessment cannot be completed from the provided metrics alone.

The portfolio is highly concentrated with only 13 total holdings, and the top 10 alone account for roughly 75% of NAV. Healthcare Services (45.6%) and Pharmaceuticals & Biotechnology (41.4%) dominate, led by Max Healthcare (9.58%), Sun Pharma (8.99%), and Sai Life Sciences (8.63%). This two-sector structure is inherent to the fund's sectoral mandate but leaves virtually no intra-sector diversification.

Without XIRR figures, the fund's standing versus the sectoral category averages — 18.42% (3Y) and 19.6% (5Y) SIP XIRR for the category — cannot be determined. The 2026 return of -3.59% suggests a weak recent year, though single-calendar-year returns are not diagnostic for sectoral funds. Investors should compare the fund's rolling returns to peers once published data is available.

As a sectoral fund concentrated in pharma and healthcare, it is suitable only for investors with high risk tolerance and the ability to tolerate sharp sector-specific drawdowns. A horizon of at least 5-7 years is recommended to ride out sector cycles, and it should be treated as a satellite allocation rather than a core holding. Novice investors or those seeking diversification should avoid sector-focused products like this one.

• Exposure to both healthcare services (45.6%) and pharmaceuticals (41.4%), capturing two distinct themes — hospitals and diagnostics as well as pharma manufacturing and CROs
• High-conviction concentrated portfolio with established leaders such as Sun Pharma, Apollo Hospitals, and Divi's Laboratories among top holdings
• Low documented drawdown metrics, with maximum drawdown of only -0.11% over a 30-day span in the measurement period

• Negative 2026 calendar year return of -3.59%, indicating weak recent performance momentum
• Extremely high concentration — only 13 holdings with the top 10 comprising roughly 75% of NAV, magnifying single-stock risk
• Missing XIRR and rolling return data makes it impossible to verify the fund's performance against the category averages of 18.42% (3Y) and 19.6% (5Y)